vs
Orthofix Medical Inc.（OFIX）与福尼克斯（PLAB）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是福尼克斯的1.0倍（$219.9M vs $210.4M），福尼克斯净利率更高（10.9% vs -1.0%，领先11.9%），Orthofix Medical Inc.同比增速更快（2.0% vs -5.5%），福尼克斯自由现金流更多（$25.2M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -3.8%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
福尼克斯是美国半导体光掩模制造商，2009年时位居全球第三大光掩模供应商，同时也是电子束产业倡议组织的成员，专注于为半导体行业提供关键的掩模产品，支撑芯片制造环节的图形转移需求。
OFIX vs PLAB — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$210.4M
营收增速更快
OFIX
高出7.5%
-5.5%
净利率更高
PLAB
高出11.9%
-1.0%
自由现金流更多
PLAB
多$8.4M
$16.8M
两年增速更快
OFIX
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $210.4M |
| 净利润 | $-2.2M | $22.9M |
| 毛利率 | 71.1% | 33.7% |
| 营业利润率 | 0.2% | 22.9% |
| 净利率 | -1.0% | 10.9% |
| 营收同比 | 2.0% | -5.5% |
| 净利润同比 | 92.4% | -32.4% |
| 每股收益（稀释后） | $-0.05 | $0.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPLAB
| Q4 25 | $219.9M | — | ||
| Q3 25 | $205.6M | $210.4M | ||
| Q2 25 | $203.1M | $211.0M | ||
| Q1 25 | $193.6M | $212.1M | ||
| Q4 24 | $215.7M | $222.6M | ||
| Q3 24 | $196.6M | $211.0M | ||
| Q2 24 | $198.6M | $217.0M | ||
| Q1 24 | $188.6M | $216.3M |
净利润OFIXPLAB
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $22.9M | ||
| Q2 25 | $-14.1M | $8.9M | ||
| Q1 25 | $-53.1M | $42.9M | ||
| Q4 24 | $-29.1M | $33.9M | ||
| Q3 24 | $-27.4M | $34.4M | ||
| Q2 24 | $-33.4M | $36.3M | ||
| Q1 24 | $-36.0M | $26.2M |
毛利率OFIXPLAB
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | 33.7% | ||
| Q2 25 | 68.7% | 36.9% | ||
| Q1 25 | 62.8% | 35.6% | ||
| Q4 24 | 69.0% | 37.0% | ||
| Q3 24 | 68.7% | 35.6% | ||
| Q2 24 | 67.8% | 36.5% | ||
| Q1 24 | 67.5% | 36.6% |
营业利润率OFIXPLAB
| Q4 25 | 0.2% | — | ||
| Q3 25 | -8.3% | 22.9% | ||
| Q2 25 | -7.9% | 26.4% | ||
| Q1 25 | -25.2% | 24.6% | ||
| Q4 24 | -5.3% | 25.1% | ||
| Q3 24 | -9.6% | 24.7% | ||
| Q2 24 | -12.5% | 25.8% | ||
| Q1 24 | -15.6% | 26.6% |
净利率OFIXPLAB
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | 10.9% | ||
| Q2 25 | -6.9% | 4.2% | ||
| Q1 25 | -27.4% | 20.2% | ||
| Q4 24 | -13.5% | 15.2% | ||
| Q3 24 | -13.9% | 16.3% | ||
| Q2 24 | -16.8% | 16.7% | ||
| Q1 24 | -19.1% | 12.1% |
每股收益（稀释后）OFIXPLAB
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | $0.39 | ||
| Q2 25 | $-0.36 | $0.15 | ||
| Q1 25 | $-1.35 | $0.68 | ||
| Q4 24 | $-0.76 | $0.54 | ||
| Q3 24 | $-0.71 | $0.55 | ||
| Q2 24 | $-0.88 | $0.58 | ||
| Q1 24 | $-0.95 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $575.8M |
| 总债务越低越好 | — | $16.0K |
| 股东权益账面价值 | $450.0M | $1.1B |
| 总资产 | $850.6M | $1.8B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资OFIXPLAB
| Q4 25 | $82.0M | — | ||
| Q3 25 | $62.9M | $575.8M | ||
| Q2 25 | $65.6M | $558.4M | ||
| Q1 25 | $58.0M | $642.2M | ||
| Q4 24 | $83.2M | $640.7M | ||
| Q3 24 | $30.1M | $606.4M | ||
| Q2 24 | $26.4M | $559.9M | ||
| Q1 24 | $27.0M | $521.5M |
总债务OFIXPLAB
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | $16.0K | ||
| Q2 25 | $157.0M | $19.0K | ||
| Q1 25 | $156.9M | $21.0K | ||
| Q4 24 | $157.0M | $25.0K | ||
| Q3 24 | $118.5M | $28.0K | ||
| Q2 24 | $118.0M | $2.5M | ||
| Q1 24 | $118.2M | $2.7M |
股东权益OFIXPLAB
| Q4 25 | $450.0M | — | ||
| Q3 25 | $442.5M | $1.1B | ||
| Q2 25 | $458.3M | $1.1B | ||
| Q1 25 | $458.3M | $1.1B | ||
| Q4 24 | $503.1M | $1.1B | ||
| Q3 24 | $525.9M | $1.1B | ||
| Q2 24 | $546.0M | $1.0B | ||
| Q1 24 | $570.3M | $1.0B |
总资产OFIXPLAB
| Q4 25 | $850.6M | — | ||
| Q3 25 | $832.6M | $1.8B | ||
| Q2 25 | $837.2M | $1.7B | ||
| Q1 25 | $823.1M | $1.7B | ||
| Q4 24 | $893.3M | $1.7B | ||
| Q3 24 | $867.9M | $1.6B | ||
| Q2 24 | $882.0M | $1.6B | ||
| Q1 24 | $906.0M | $1.6B |
负债/权益比OFIXPLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | 0.00× | ||
| Q2 25 | 0.34× | 0.00× | ||
| Q1 25 | 0.34× | 0.00× | ||
| Q4 24 | 0.31× | 0.00× | ||
| Q3 24 | 0.23× | 0.00× | ||
| Q2 24 | 0.22× | 0.00× | ||
| Q1 24 | 0.21× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $50.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $25.2M |
| 自由现金流率自由现金流/营收 | 7.6% | 12.0% |
| 资本支出强度资本支出/营收 | 4.9% | 11.8% |
| 现金转化率经营现金流/净利润 | — | 2.19× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $64.5M |
8季度趋势，按日历期对齐
经营现金流OFIXPLAB
| Q4 25 | $27.7M | — | ||
| Q3 25 | $12.4M | $50.1M | ||
| Q2 25 | $11.6M | $31.5M | ||
| Q1 25 | $-18.4M | $78.5M | ||
| Q4 24 | $23.7M | $68.4M | ||
| Q3 24 | $11.7M | $75.1M | ||
| Q2 24 | $9.0M | $76.5M | ||
| Q1 24 | $-18.6M | $41.5M |
自由现金流OFIXPLAB
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | $25.2M | ||
| Q2 25 | $4.5M | $-29.1M | ||
| Q1 25 | $-25.1M | $43.3M | ||
| Q4 24 | $15.2M | $25.2M | ||
| Q3 24 | $6.3M | $50.7M | ||
| Q2 24 | $-360.0K | $56.5M | ||
| Q1 24 | $-29.1M | $-1.8M |
自由现金流率OFIXPLAB
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | 12.0% | ||
| Q2 25 | 2.2% | -13.8% | ||
| Q1 25 | -13.0% | 20.4% | ||
| Q4 24 | 7.0% | 11.3% | ||
| Q3 24 | 3.2% | 24.0% | ||
| Q2 24 | -0.2% | 26.0% | ||
| Q1 24 | -15.4% | -0.8% |
资本支出强度OFIXPLAB
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | 11.8% | ||
| Q2 25 | 3.5% | 28.7% | ||
| Q1 25 | 3.5% | 16.6% | ||
| Q4 24 | 4.0% | 19.4% | ||
| Q3 24 | 2.7% | 11.6% | ||
| Q2 24 | 4.7% | 9.2% | ||
| Q1 24 | 5.6% | 20.0% |
现金转化率OFIXPLAB
| Q4 25 | — | — | ||
| Q3 25 | — | 2.19× | ||
| Q2 25 | — | 3.55× | ||
| Q1 25 | — | 1.83× | ||
| Q4 24 | — | 2.02× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | 1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
